IDENTIFICATION AND CHARACTERIZATION OF NEW IMPURITIES IN DEXAMETHASONE OPHTHALMIC SUSPENSION
DOI:
https://doi.org/10.22159/ijap.2025v17i5.53923Keywords:
Dexamethasone ophthalmic suspension, High-resolution mass spectrometry, Impurity isolation, Nuclear magnetic resonance, Ultra-performance liquid chromatography methodAbstract
Objective: This study was intended to identify two unknown impurities (Imp-A and Imp-B) observed at trace level in the six-month stability samples of dexamethasone ophthalmic suspension subjected to accelerated conditions (40 °C/75% relative humidity) using chromatographic and spectroscopic techniques.
Methods: During a six-month stability study of dexamethasone ophthalmic suspension, two unknown impurities were detected at level of exceeding the specification (0.20%) in chromatographic analysis. Impurities were isolated, enriched by preparative HPLC and characterized by using sophisticated spectroscopic techniques, including nuclear magnetic resonance (NMR), high-resolution mass spectrometry (HR-MS) and infrared (IR). Efficient and selective separation of these impurities was achieved using ultra-high performance liquid chromatography (UHPLC) on a Waters Acquity Bio H-Class System with XBridge C18 column (150 mm × 4.6 mm, particle size 3.5 µm) column at 40 °C. The mobile phase consisted of 0.02M ammonium formate and acetonitrile with detection at 240 nm using a photodiode array (PDA) detector. The results demonstrated that this mass-compatible UPLC method is suitable for the identifying and quantifying Imp-A and Imp-B in the dexamethasone ophthalmic suspension samples.
Results: Two impurities were formed in dexamethasone ophthalmic suspension samples under accelerated stability conditions, which were identified by spectroscopic techniques like LC-HRMS, NMR (1D and 2D) and IR. Major structural modifications of Imp-A and Imp-B with respect to dexamethasone were found on carbon C17. Mono-isotopic mass of 379.1921 [M+H]+and empirical formula of C21H28FO5 for Imp-A, and mono-isotopic mass of 407.1838 [M+H]+and empirical formula of C22H28FO6 for Imp-B observed during LC-HRMS study found in line with theoretical mono-isotopic mass and empirical formula for both impurities. The chemical shifts and splitting patterns observed in the 1D and 2D NMR spectra indicated the presence of a steroidal ring system in both impurities, consistent with the core structure of dexamethasone, suggesting that Imp-A and Imp-B are structurally related to the parent compound. The 2D 1H-13C HSQC spectra of Imp-A and Imp-B revealed correlations between hydrogen and carbon atoms, supporting their structural relationship with dexamethasone. Additionally, 1H-13C HMBC spectra confirmed the presence of a conjugated steroidal ring system in both impurities. Based on the combined LC-HRMS and NMR data, the structures of Imp-A and Imp-B were characterized and found to be related to dexamethasone.
Conclusion: The LC-HRMS method developed for the identification of unknown impurities of dexamethasone was found to be highly sensitive and selective. This method is capable of detecting trace level of impurities in dexamethasone and can used for the identifying unknown impurities of dexamethasone drug product. Combination of different spectroscopic techniques provides a pivotal tool for elucidating the structure impurities at trace level.
References
1. Gorog S. Critical review of reports on impurity and degradation product profiling in the last decade. TrAC Trends Anal Chem. 2018 Apr;101:2-16. doi: 10.1016/j.trac.2017.09.012.
2. Dispas A, Avohou HT, Lebrun P, Hubert P, Hubert C. Quality by design approach for the analysis of impurities in pharmaceutical drug products and drug substances. TrAC Trends Anal Chem. 2018 Apr 1;101:24-33. doi: 10.1016/j.trac.2017.10.028.
3. Himabindu G, Reddy YS, Prasad AV, Ramadas C, Sharma HK. New stability indicating RP-HPLC methods for the determination of related substances and assay of trametinib acetic acid: a mass balance approach. Anal Sci. 2024 Nov;40(11):2005-15. doi: 10.1007/s44211-024-00633-4, PMID 39080194.
4. Brunton LL, Knollmann BC. Goodman and gilmans: the pharmacological basis of therapeutics. 14th ed; 2022.
5. Schepers A, Pires NM, Eefting D, De Vries MR, Van Bockel JH, Quax PH. Short-term dexamethasone treatment inhibits vein graft thickening in hypercholesterolemic ApoE3Leiden transgenic mice. J Vasc Surg. 2006 Apr;43(4):809-15. doi: 10.1016/j.jvs.2005.11.019, PMID 16616241.
6. Muller DW, Golomb G, Gordon D, Levy RJ. Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. Coron Artery Dis. 1994 May;5(5):435-42. doi: 10.1097/00019501-199405000-00010, PMID 7921375.
7. Strecker EP, Gabelmann A, Boos I, Lucas C, Xu Z, Haberstroh J. Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries. Cardiovasc Intervent Radiol. 1998 Nov-Dec;21(6):487-96. doi: 10.1007/s002709900309, PMID 9853167.
8. Hoffmann R, Langenberg R, Radke P, Franke A, Blindt R, Ortlepp J. Evaluation of a high-dose dexamethasone-eluting stent. Am J Cardiol. 2004 Jul 15;94(2):193-5. doi: 10.1016/j.amjcard.2004.03.061, PMID 15246899.
9. Owji N, Khalili MR, Khademi B, Shirvani M, Sadati MS. Comparison of the effectiveness of onion extract topical steroid and petrolatum emollient in cosmetic appearance of upper blepharoplasty scar. J Curr Ophthalmol. 2020 Dec 12;32(4):408-13. doi: 10.4103/JOCO.JOCO_39_20, PMID 33553845.
10. Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis. Adv Ther. 2007 Jan-Feb;24(1):60-7. doi: 10.1007/BF02849993, PMID 17526462.
11. Notivol R, Amin D, Whitling A, Wells D, Kennedy M, Cockrum PC. Prophylactic effectiveness of tobramycin dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients: prospective randomised double masked two arm parallel group placebo-controlled multicentre study. Clin Drug Investig. 2004;24(9):523-33. doi: 10.2165/00044011-200424090-00003, PMID 17523714.
12. Notivol R, Bertin D, Amin D, Whitling A, Kennedy M, Cockrum PC. Comparison of topical tobramycin dexamethasone with dexamethasone neomycin polymyxin and neomycin polymyxin gramicidin for control of inflammation after cataract surgery: results of a multicenter prospective three-arm randomized double masked controlled parallel group study. Clin Ther. 2004;26(8):1274-85. doi: 10.1016/s0149-2918(04)80113-9, PMID 15476908.
13. Impurities in new drug substances International Conference on harmonization (ICH). 2006;Q3A:R2. Available from: https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf.
14. Ummiti K, Vakkala S, Panuganti V, Annarapu MR. Isolation identification and characterization of 17-oxo dexamethasone an oxidative degradation impurity of dexamethasone using flash chromatography and NMR/HRMS/IR. J Liq Chromatogr Relat Technol. 2014 May;37(17):2403-19. doi: 10.1080/10826076.2013.836712.
15. Chen Q, Zielinski D, Chen J, Koski A, Werst D, Nowak S. A validated stability indicating HPLC method for the determination of dexamethasone related substances on dexamethasone coated drug eluting stents. J Pharm Biomed Anal. 2008 Nov 4;48(3):732-8. doi: 10.1016/j.jpba.2008.07.010, PMID 18722070.
16. Surukonti SR, Manabolu Surya SB, Katari NK, Yerla RR. Investigating betrixaban maleate drug degradation profiles isolation and characterization of unknown degradation products by mass-triggered preparative HPLC HRMS and NMR. J Pharm Biomed Anal. 2023 Oct 25;235:115643. doi: 10.1016/j.jpba.2023.115643, PMID 37633165.
17. Ketha NV, Kolli D, Subbappa PK. Structural elucidation of novel degradation impurity and development validation of a single HPLC method for all putative impurities of clobetasol propionate in a foam drug product. J Chromatogr Sci. 2024 May 31;62(5):444-53. doi: 10.1093/chromsci/bmad016, PMID 36857571.
18. Karatt TK, Nalakath J, Perwad Z, Albert PH, Abdul Khader KK, Syed Ali Padusha M. Mass spectrometric method for distinguishing isomers of dexamethasone via fragment mass ratio: an HRMS approach. J Mass Spectrom. 2018 Nov;53(11):1046-58. doi: 10.1002/jms.4279, PMID 30098588.
19. Arvaniti OS, Ioannidi AΑ, Politi A, Miserli K, Konstantinou I, Mantzavinos D. Dexamethasone degradation in aqueous medium by a thermally activated persulfate system: kinetics and transformation products. J Water Process Eng. 2022 Oct;49:103134. doi: 10.1016/j.jwpe.2022.103134.
20. Sudha D, Malarkodi R, Gokulakrishnan A, Liyakath Ali AR. LC-MS/MS and GC-MS profiling and the antioxidant activity of Carissa carandas Linn. Int J Pharm Pharm Sci. 2024 Jun;16(6):39-45. doi: 10.22159/ijpps.2024v16i6.50818.
21. Patole S, Gosar A, Shaikh T. Impurities characterization in pharmaceuticals: a review article. Int J Pharm Pharm Res. 2019 Jul;15(4):46-64.
22. Rathore MK, Mohan Reddy TR. Tandem mass spectrometric method for the trace level determination of 2-aminopyridine: a potential genotoxic impurity in tenoxicam API. Int J Pharm Pharm Sci. 2024 Apr;16(4):50-6. doi: 10.22159/ijpps.2024v16i4.49902.
23. Rajagopaludu P, Saritha N, ND, Maddi S. Method development and validation of erythromycin and olaparib in human plasma by liquid chromatography tandem mass spectrometry. Asian J Pharm Clin Res. 2022;15(4):28-33. doi: 10.22159/ajpcr.2022.v15i4.44044.
24. Bodke SS, Bhangale CJ, Bhandare SN. Stability indicating UPLC method for estimation of benazepril and hydrochlorothiazide in bulk and combined dosage form. Int J Pharm Pharm Sci. 2024 Jan;16(1):22-9. doi: 10.22159/ijpps.2024v16i1.49457.
25. Matter B, Ghaffari A, Bourne D, Wang Y, Choi S, Kompella UB. Dexamethasone degradation in aqueous medium and implications for correction of in vitro release from sustained release delivery systems. AAPS PharmSciTech. 2019 Oct 23;20(8):320. doi: 10.1208/s12249-019-1508-7, PMID 31646399.
26. Dembitsky VM. Biological activity and structural diversity of steroids containing aromatic rings, phosphate groups or halogen atoms. Molecules. 2023 Jul 20;28(14):5549. doi: 10.3390/molecules28145549, PMID 37513423.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Raju Mudhulkar, Bhupinder Kumar
This work is licensed under a Creative Commons Attribution 4.0 International License.
